February 25, 2022 06:03 AM ESTUpdated 09:18 AM

Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Derek Graf

As market volatility sweeps through the landscape, CEO changes are really ramping up, and topping the list is Tillman Gerngross, a force in the antibody …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ther­a­py ex­ec from No­var­tis

Senior Editor

Editor

Sign up to read this article for free.

Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis